Category Archives: Stem Cell Doctors


Lymph nodes: Purpose, location, and disease warning signs – Medical News Today

Lymph nodes are small, bean-shaped glands that play a crucial role in the immune system. They filter lymphatic fluid, which helps rid the body of germs and remove waste products.

The body contains hundreds of lymph nodes. They form clusters around the body and are particularly prominent in areas such as the neck, armpit and groin and behind the ears.

The bodys cells and tissues dispose of waste products in lymphatic fluid, which lymph nodes then filter. During this process, they catch bacteria and viruses that could harm the rest of the body.

Lymph nodes are an essential part of the bodys immune system. Due to their function, they come into contact with toxins, which can cause them to swell. Although swollen lymph nodes are common, they may occasionally indicate lymph node cancer, or lymphoma.

Keep on reading to learn more about lymph nodes and their function within the immune system.

Lymph nodes are part of the lymphatic system, which is a complex network of nodes and vessels.

In certain areas of the body, such as the neck, armpit, and groin, lymph nodes sit close to the skin. This means a person may feel them swell when an infection develops.

Lymph nodes are also present in the stomach and between the lungs. However, there are no lymph nodes in the brain or spinal cord.

The name of a lymph node depends on its location in the body.

Lymph nodes form clusters throughout the body. Their main function is to filter out potentially harmful substances.

All tissues and cells in the body excrete lymphatic fluid, or lymph, in order to eliminate waste products. The lymph then travels through vessels in the lymphatic system and passes through lymph nodes for filtering.

Lymph nodes contain lymphocytes. These are a type of white blood cells that help destroy pathogens, such as bacteria, viruses, and fungi. When lymph nodes detect a pathogen in the lymph, they produce more lymphocytes, which causes them to swell.

Upon encountering bacteria or damaged cells, lymph nodes destroy them and turn them into a waste product.

When the lymph reenters the bloodstream, waste products travel to the kidneys and liver. The body then excretes waste products in the urine and feces.

Learn more about how the lymphatic system works here.

Swollen lymph nodes do not always indicate cancer. Below, we list some of many conditions that can cause lymph node swelling.

Lymphadenitis occurs when bacteria, viruses, or fungi in the lymph infect lymph nodes. When this happens, lymph nodes swell and are painful to the touch.

If multiple clusters of nodes become infected, a person may feel pain and swelling in both their neck and groin.

The most common type of lymphadenitis is localized lymphadenitis. This means the condition only affects a few nodes. If the infection occurs in several node clusters, a doctor will likely diagnose generalized lymphadenitis.

The condition usually results from an infection elsewhere in the body.

Symptoms of lymphadenitis include:

Lymphadenitis treatments include:

The type of treatment necessary will depend on a variety of factors, such as the severity of the disease and a persons underlying conditions and allergies. A doctor will help a person choose the most suitable treatment based on these factors.

Learn more about swollen lymph nodes in the neck here.

Swollen lymph nodes in the neck may be due to a viral or bacterial throat infection, such as strep throat.

Viral throat infections, such as colds, can present with swollen lymph nodes, a runny nose, and pinkeye.

These infections usually resolve on their own. However, a person can take over-the-counter pain relievers to alleviate pain they may experience when swallowing.

Strep throat is a bacterial infection that develops in the throat and tonsils due to group A streptococcus. People may contract strep throat if they come into contact with droplets containing the strep bacteria.

A person with strep throat may experience swollen lymph nodes on the neck, a sore throat, a fever, and red spots on the roof of the mouth.

Doctors treat strep throat with antibiotics.

Impetigo is an infection that develops due to group A streptococcus and may cause lymph nodes in the armpits and groin to swell.

A person can contract impetigo when the bacteria enter the body through a break in the skin. This can happen through sharing a towel, razor, or yoga mat.

Symptoms of impetigo include:

If a person has impetigo, they should seek medical attention to address their symptoms and prevent the condition from spreading to others.

Treatment will usually involve antibiotics.

Ringworm, or jock itch, is a fungal infection that can affect many areas of the body. If the fungus develops in the groin, a person may experience lymph node swelling in that area.

Typically, ringworm starts as a fungal lesion. The fungus often transmits when people share towels or razors.

Ringworm thrives in moist environments, and therefore a person should take care to dry thoroughly after a wash and try not to stay in damp clothes.

Common ringworm symptoms include:

A doctor will prescribe an antifungal treatment to address ringworm.

The best way to prevent ringworm is to wear breathable fabrics, avoid sharing towels and razors, and dry thoroughly after bathing.

Learn more about swollen lymph nodes in the groin here.

Lymphoma is a type of cancer that affects the lymphatic system. The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma.

Hodgkin lymphoma occurs when cancer cells spread from one cluster of lymph nodes to another. By contrast, in non-Hodgkin lymphoma, there is no order in how cancer cells spread throughout the lymphatic system.

Typical symptoms of lymphoma include:

These are also common symptoms of viral infections, which can make lymphoma hard to diagnose. However, in people with lymphoma, symptoms tend to persist for longer periods of time.

It is of note that these symptoms do not clearly indicate cancer. If a person experiences any of these, they should contact a doctor to identify the cause of their symptoms.

Treatment options for lymphoma include:

A person should contact a healthcare professional if they are experiencing persistent swelling of lymph nodes.

Swelling usually indicates an infection, and therefore a person should not immediately worry about lymphoma.

After reaching a diagnosis, a doctor will recommend the appropriate course of treatment.

Lymph nodes are a part of the lymphatic system. They filter lymph, which contains pathogens and damaged cells, and send the dead cells to the kidneys and liver.

Lymph node swelling usually results from an infection. In rare cases, however, it may be due to lymphoma.

If a person is concerned about swelling and other symptoms they have, they should contact a doctor.

The rest is here:
Lymph nodes: Purpose, location, and disease warning signs - Medical News Today

Teesside baby will be third in country to have ground breaking complex cancer treatment – Teesside Live

Teesside tot Olivia-Grace Corcoran was flying to London with her family today to start ground breaking treatment in a bid to cure her leukaemia.

The six month old, from Dormanstown, near Redcar, will become only the third person in the country - and the youngest - to undergo a complex and specialist treatment called CAR T cell therapy.

She was diagnosed with a form of acute leukaemia in March at the age of just four months after starting to repeatedly vomit her baby milk back up.

The beautiful little girl, who her family describe as nothing short of amazing, has already undergone chemotherapy to try to beat the disease and was due to have a stem cell transplant at Newcastle's RVI.

Instead, doctors have taken the decision to fly her to London's Great Ormond Street Hospital for the highly specialist treatment in a bid to stabilise her condition.

Her dad Jordan, 22, a plumber, and mum Chloe Kirk, 20, will fly with her to the hospital on Tuesday, June 8, for initial tests. She'll then have to spend three months in the capital whilst the complex procedure is carried out.

Jordan said he hasn't had time yet to process the enormity of the situation, instead the young family are concentrating their energy on Olivia-Grace and tackling things as they come.

"It came as a shock when they said go to London, we weren't expecting it," said Jordan.

"We thought we'd be in the RVI in Newcastle but after speaking with the doctors, they wanted to do this new therapy at Great Ormond Street Hospital.

"Olivia-Grace is fine, she's really content and she just seems to get on with things really well."

CAR T cell therapy involves taking a sample of T cells from the blood - the type of cells that fight infection and diseases. They are then taken to a lab and genetically modified to try and get them to recognise cancer cells.

Once they have grown and multiplied, the cells are then dripped back into the bloodstream. The aim is for the CAR T cells to then attack the cancer cells.

In Olivia-Grace's case, says Jordan, the initial T cells will come from an adult blood donor.

The family have been told she is only the third person to have it, and the youngest.

"It makes you wonder who thought of doing that in the first place - but whoever it was, thank you," said Jordan.

After initial bone marrow tests, the young family hope to be back on Teesside on Wednesday. From then, depending on results, Olivia-Grace will have to spend three months at the London hospital.

If the CAR T cell therapy works, the hope is she'll then be able to have a stem cell transplant as planned.

Chloe will stay with her, says Jordan, and the hope is that his mum will be able stay with them too. Jordan works full time but hopes he'll be able to travel up and down to Great Ormond Street Hospital every weekend to be with his family.

To sign up for Teesside Live news updates, go here

The Dormanstown community have already rallied round with their support by organising a number of fundraising initiatives to help the young family. You can find their GoFundMe page here.

Originally posted here:
Teesside baby will be third in country to have ground breaking complex cancer treatment - Teesside Live

Brave Nathaniel Nabena, 9, all smiles as he has life-saving procedure – thanks to you – The Mirror

Brave Nathaniel Nabena smiles from his hospital bed moments before a life-saving procedure.

The nine-year-old had a vital stem cell transplant at Great Ormond Street Hospital on Wednesday after Sunday People readers helped raised more than 215,000.

Nathaniel, battling acute myeloid leukaemia, was on a drip for 30 minutes as umbilical cord stem cells were fed into his body.

Afterwards, dad Ebi said: Nathaniel is very happy. It was amazing to finally get to this point we have all been waiting for.

The youngster was admitted a fortnight ago and had five doses of chemo over ten days to prepare him for the procedure.

How brave has Nathaniel been? Have your say in comments below

Mum Modupe, 38, was able to spend time with him before his transplant.

Consultants warn he faces weeks of sickness as his body reacts to the new cells with symptoms including vomiting and a fever.

Ebi, 45, said: His doctors hope to see improvements after five weeks. It is so hard to see him so exhausted but I dont have a choice. We are grateful to have this done. Our fingers are crossed to see what happens.

For now, Nathaniel has a compromised immune system and is susceptible to falling ill, so he will be staying on the ward.

Stars including Simon Cowell, David Walliams, Katie Price and JLS singer Aston Merrygold rallied to support him after we told of the desperate race to fund treatment.

Nathaniels left eye was removed in his home country of Nigeria a year ago, due to myeloid sarcoma cancer. He was diagnosed with AML in the UK in November after coming here to have a prosthetic eye fitted.

Nathaniel was told a stem-cell transplant was his only hope for survival but it would cost 201,000 as he is not a British citizen. Ebi and Modupe were initially told it could cost as much as 825,000 but the figure was revised after doctors waived their fees and offered to treat him in their own time.

The Mirror's newsletter brings you the latest news, exciting showbiz and TV stories, sport updates and essential political information.

The newsletter is emailed out first thing every morning, at 12noon and every evening.

Never miss a moment by signing up to our newsletter here.

The lad was admitted to GOSH on May 24 after generous Brits rushed to help the family raise cash.

Business analyst Ebi, who is staying at the hospitals family quarters, said: Ive been there the whole time. When he is not sleeping he is passing the time playing his games.

We sometimes talk about when he gets better and how exciting that will be. This is a difficult thing for him to go through, but Nathaniel is being brave, he is well in himself.

In acute myeloid leukaemia, unhealthy blood-forming stem cells grow quickly in the bone marrow.

This prevents it from making normal red blood cells, white blood cells and platelets meaning the body cannot fight infections or stop bleeding.

A stem cell transplant, also known as a bone marrow transplant, can help AML patients stimulate new bone marrow growth and restore the immune system.

Before treatment, patients need high doses of chemo and sometimes radiotherapy.

This destroys existing cancer and bone marrow cells and stops the immune system working, to cut the risk of transplant rejection.

In an allogeneic transplant, stem cells are taken from a family member, unrelated donor or umbilical cord blood. In Nathaniels case, it was from a cord.

They are then passed into the patients body through a line inserted in a large, central vein, in a process that takes up to two hours.

You can also remove stem cells from the patients body and transplant them later, after any damaged or diseased cells have been removed this is called an autologous transplant.

The survival rate after a transplant for patients with acute leukaemia in remission and using related donors is 55% to 68%, according to Medicine Net. If the donor is unrelated, it is 26% to 50%.

See the original post:
Brave Nathaniel Nabena, 9, all smiles as he has life-saving procedure - thanks to you - The Mirror

Local veterinary clinics offer integrated care options for pets – williamsonherald.com

After graduating from the University of Tennessee College of Veterinary Medicine and practicing in the field for several years, Dr. Mitch McKee began to explore alternative treatment methods that would improve his four-legged patients lives, working collaboratively with conventional treatments and therapies.

McKee went on to pursue various accreditations in holistic veterinary medicine from Chi University in Reddick, Florida, including a masters degree in traditional Chinese veterinary medicine, making him one of only approximately 300 people across the country with this certification.

He now incorporates these accreditations and practices into his treatments daily for patients at both Cupola Animal Hospitals locations, including Berry Farms Animal Hospital in Franklin and Concord Road Animal Hospital in Brentwood.

Using both traditional and holistic methods of medicine allows us to provide our patients and their owners with the best of both worlds, McKee said. Western medicine is great, we love it and need it, but its more of a one-size-fits-all method. You tend to treat the problem and not the patient. With an integrated approach, Chinese methods and holistic practices allow us to individualize therapy so that we treat the underlying issue that led to the problem at hand, often with fewer side effects.

McKee and his fellow certified veterinary acupuncturist at Cupola, Dr. Ben Larson, are among just a handful of veterinarians in the Middle Tennessee area qualified to use acupuncture, and they utilize it as a treatment option regularly. Both clinics offer three types of acupuncture, which has been shown to initiate healing and decrease pain to improve a patients quality of life.

The clinics also offer chiropractic care, food therapy, massage therapy, herbal medicine, stem cell therapy, and ozone (O3) therapy in addition to acupuncture, treatment options the doctors recommend for a number of animal patients.

Any patient, regardless of age or medical issue, can benefit from these integrated therapies, McKee said. You can utilize them one time for a particular situation, or monthly, or however often you need to. Theres a great deal of flexibility with offering multiple modalities of therapy, and weve found that using them can decrease the need for expensive or risky surgeries. We have witnessed countless success stories with our patients that demonstrate these treatment options are effective and reliable.

Berry Farms Animal Hospital recently celebrated its fourth anniversary in March, and Concord Road celebrated its second anniversary last month. To learn more about the clinics or to make an appointment, visit CupolaAnimalHospitals.com.

Follow this link:
Local veterinary clinics offer integrated care options for pets - williamsonherald.com

Blood cancer and leukaemia: UAE oncologist urges public to spot the symptoms – The National

A leading oncologist has urged the public to be aware of the symptoms of blood cancer and leukaemia amid a global rise in new cases.

Dr Shahrukh Hashmi, chair of the haematology and oncology department at Abu Dhabi's Sheikh Shakhbout Medical City, said too many cases were diagnosed in the advanced stage.

Leukaemia is a group of blood cancers that usually develop in the bone marrow and the lymphatic system.

It is among the 10 most prevalent cancers globally and according to studies has been on the rise in recent years. The five-year survival rate in the United States is about 57 per cent.

The one thing that the public can take charge of is active surveillance, with regular pap smears, colonoscopies and mammograms

Dr Shahrukh Hashmi, Sheikh Shakhbout Medical City, Abu Dhabi

We have hundreds of cases recorded every year but it is very likely that there are even more that go unrecorded, because many go underdiagnosed or misdiagnosed," said Dr Hashmi, a specialist in late-stage chemotherapy treatment and cancer survivability.

Less is known about the causes of leukaemia and lymphoma than many other cancers. Exposure to certain chemicals, genetic disorders, family history and smoking are known to be factors.

Some studies have linked blood cancers to a rise in pollution.

Dr Hashmi believes more research is needed in the Gulf and UAE to understand the causes.

He said environmental factors could play a part, along with "inheritable cancers due to consanguineous marriages".

We have not yet had any epidemiological studies giving the exact cause of the significantly higher ratio of blood cancers to solid cancers in the UAE," he said.

_______________________

- fever or chills

- persistent fatigue, weakness

- frequent or severe infections

- losing weight without trying

- swollen lymph nodes, enlarged liver or spleen

- excessive sweating, especially at night

Source: Mayo Clinic

_______________________

Dr Hashmi said too many patients shuttle between smaller hospitals and undergo a myriad of referrals before they reach a specialist cancer ward.

The biggest problem I see here is the dissipation of care. Many patients will go to several hospitals before finally landing at tertiary care centres like SSMC," he said.

By the time they come here they already have been to three or even four hospitals which delays care.

Last month, a study shed light on the high prevalence of cancer in UAE and Saudi Arabia.

The analysis of 2017 data from major developed countries showed almost half of all cancer cases in the UAE involved people aged under 50.

Dr Abdulmajeed Alzubaidi takes The National on a tour of the facilities

Abu Dhabi's new Sheikh Shakhbout Medical City opened towards the end of 2019. All photos by Chris Whiteoak / The National

A sculpture in the foyer of the sprawling hospital

The emergency department can handle hundreds of patients

The hospital is located on a large campus outside the city

A state-of-the-art surgical theatre

Floor to ceiling windows allow for plenty of natural light

The hospital is jointly run by America's top-ranked medical group - Mayo Clinic - and Abu Dhabi public hospital operator Seha

A view from outside Sheikh Shakhbout hospital

An air conditioned walk way connects hospital wings and parking facilities

The hospital's location allows for large rooms and wards

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The studys authors, from University of Sharjah's College of Medicine, said the trend was a "critical issue that is currently underreported".

As with global trends, breast cancer was most prevalent accounting for 36 per cent of all cases followed by several forms of colorectal cancers.

The latter in particular is closely linked to lifestyle choices, including bad diet, smoking and drinking alcohol.

Dr Hashmi said better lifestyles, high public awareness and regular screening of people of all ages will save lives.

"The one thing that the public can take charge of when it comes to cancer is active surveillance," he said.

"People should get regular screenings for cancers such as pap smears, colonoscopies and mammograms. These are preventative measures that have been around for decades in Europe and the US.

"Our screening rates are low and we are really hoping it can go up, especially for the most common cancer we know of, breast cancer.

For blood cancers, some of the common symptoms are fatigue and persistent swollen lymph nodes.

Acute leukaemia patients will generally need a bone marrow or stem cell transplant.

Despite advances in the UAE's organ transplant programme, including the first bone marrow transplant in 2020, many patients travel abroad for treatment.

Sheikh Shakhbout Medical City will have its own transplant centre set up by the final three months of 2021.

For patients such as 34-year-old Mohammad Hoda, an electrician who works for a company in Abu Dhabi, it cannot open too soon.

He is undergoing chemotherapy at SSMC and his doctors are working with hospitals in India to try to find a suitable donor for a bone marrow transplant.

The Indian father-of-four was found with advanced leukaemia just over a month ago.

"I was feeling very tired and had severe pain in my body. I also had a few nose bleeds," he said.

When The National visited his hospital room last week, he was hopeful that medics in India will find a match, giving a thumbs up as he posed for a photograph.

But like all organ transplant patients, has no way of knowing if and how long it could take to find a donor.

"It is hard that I am alone here without my family, and my future is uncertain," he said.

View original post here:
Blood cancer and leukaemia: UAE oncologist urges public to spot the symptoms - The National

Replotting the human: the thorny ethics of growing babies outside the womb – Prospect

In its worthy pursuit of what the philosopher Francis Bacon called the relief of mans estate, science has a habit of creating previously unknown moral dilemmas. Thats nowhere more apparent than in the sciences pertaining to the beginning of human lives.

When IVF took off after the birth of Louise Brown in 1978, fertility doctors were faced with the question of what to do with embryos produced in vitrothat is, outside the wombwhich would not, either because of their unviability or sheer excess in number, be implanted for gestation. Many were donated for embryological research, which has made huge strides as a result. But this has also complicated the already impassioned argumentsstill unresolvedabout the moral status of the human embryo.

Similar wrangles loom over the recent report in Nature by a team of scientists based in Israel who say that they can gestate mouse embryos in glass jars for up to 12 days. That might not sound long, but it is half a mouses normal gestation period: the embryos can reach a stage where the internal organs are in place, the heart is beating, and the hind legs are developing.

By contrast, no human embryos have been grown outside the womb beyond 14 days (the legal limit in the UK, Israel, China and many other countries), which is of course still at a very early stage of the journey towards becoming a baby. But Jacob Hanna, who led the Israeli project at the Weizmann Institute of Science, told Technology Review that it sets the stage for other species I hope that it will allow scientists to grow human embryos until week five.

At the same time, advances in biology are enabling the creation of entirely new types of embryo-like structures, which some call simbryos, by assembling from scratch the embryonic cells of humans and other animals. Because these entities are in some sense artificial, though made from ordinary living cells, researchers arent sure if they qualify as genuine embryos, and so whether they should fall under the 14-day legal constraint. Meanwhile, scientists in the US and China have recently reported making chimeric embryos that contain a mixture of human and monkey cells, which they could keep alive in vitro for up to 20 days.

All these studies are motivated by biomedical questions and needs, from trying to understand the early stages of human development (and what can go wrong, for example, leading up to miscarriages) to trying to grow human organs for transplants within livestock animals. Yet they are also blurring boundaries: between natural and artificial, tissue culture and actual conception, humans and other species. We are, in the words of academic Susan Merrill Squier, replotting the humanand, so far, with no moral framework to guide us.

We havent even decided what the important questions are, let alone how to answer them

When the Warnock Committee, chaired by moral philosopher Mary Warnock, was established in 1982 to navigate the thicket opened up by IVF, it intentionally ducked the issue of the human embryos moral status. A key strategy of the Warnock Committee, says Sarah Franklin, director of the Reproductive Sociology Research Group at Cambridge, was to eschew the moral debate, for the simple reason it can never be resolved. The committees recommendation of the 14-day rule was pragmatic: this is roughly the point after which an embryo cannot split into twins, and so served as an otherwise entirely arbitrary kind of proxy for personhood. No more rigour was needed because there was not at that stage any practical possibility of going beyond that line.

But technological advances mean that governments and scientific bodies are reconsidering the 14-day ruleand thereby taking the lid back off the moral debate. Simbryos might simply sidestep itbut should they? These are dilemmas that science has created but cannot answer. The great danger is that, amid the murk, we will grab onto polarised ideologies in the hope of settling things.

Eugenic hatcheries

Arguments about embryology have long been divisive, and come weighted down with heavy cultural baggage. Growing embryos and even babies ex utero was christened ectogenesis in the early 20th century; its possibility motivated the biologist JBS Haldane to write Daedalus, or Science and the Future in 1924. Haldane presented a fictionalised future in which ectogenesis was introduced in the 1950s to combat plummeting birth rates. His narrator explains that, by 2073, less than a third of children were still born of woman.

Haldane welcomed this prospect. First, he said, it would allow population increase to be rationally planned and controlled. Better still, it would be possible to control who reproduced. Like many of his progressive contemporaries, while he supported female emancipation, he worried that better educated, well-bred women would prefer their new opportunities over their traditional role as mothers, leading to a decline in the quality of the gene pool. Ectogenesis could facilitate the necessary corrective of eugenic engineering. An enthusiasm for eugenics was shared by Haldanes friend Julian Huxley, who served as vice president and then president of the British Eugenics Society from 1937 to 1962. (No, eugenic advocacy was not killed off by the example of the Nazis.)

But Huxleys brother Aldous was less taken with Haldanes vision of a bioengineered population grown in artificial wombs. That scenario supplied the inspiration for the dystopian Brave New World (1932), with its hatcheries in which foetuses are chemically manipulated for intelligence to create the hierarchical society of the World State.

At one time, both men and women sympathetic to the feminist cause welcomed ectogenesis. In Hymen, or The Future of Marriage (1927), Norman Haire suggested that animals might instead act as gestational surrogates: human babies born to chimp mothers, for example. The pioneering feminist Vera Brittain, however, conceded in Halcyon, or the Future of Monogamy (1929) that natural methods of reproduction might make a comeback after a period of ectogenesis because children born outside the womb could suffer psychological problems. The trailblazing feminist writer Shulamith Firestone was another fan of ectogenesis. Her 1970 book The Dialectic of Sex portrayed childbearing as a primary cause of gender inequality: I submit, she wrote, that the first demand for any alternative system must be the freeing of women from the tyranny of their reproductive biology by every means available.

For all its humanitarian objectives, embryonic research remains ethically fraught

In stark contrast, more recent feminists have warned that artificial wombs could remove from women a source of social power. Australian sociologist Robyn Rowland worries: We [women] may find ourselves without a product of any kind with which to bargain if that last power is taken and controlled by men, what role is envisaged for women in the new world? Will women become obsolete? Another worry is expressed by bioethicist Rosemarie Tong, who fears a commodification of the whole process of pregnancy [and] a view of the growing child as a thing.

History shows, then, that while putative reproductive technologies like ectogenesis and artificial wombs have long been controversial, the terms of the debate have shifted with social perceptions and attitudes. We havent even decided what the important questions are, let alone how to answer them.

Towards artificial wombs

True ectogenesis is still a far cry from what the Israeli group has just achieved. Their mouse embryos do not really exist in an artificial womb as such; they float freely in a nutrient medium, including human blood serum taken from the umbilical cord, in rotating glass jars kept at a carefully controlled temperature and in levels of dissolved oxygen elevated above normal. Because they have no placenta to attach to or umbilical cord to supply blood, eventually they die through lack of oxygen.

The work is impressive, but growing small mammal embryos far into gestation in artificial cell-culture conditions is not completely new. For example, developmental biologist Lynne Selwood at the University of Melbourne has been able to culture embryos of the stripe-face dunnarta mouse-like marsupialto within a few hours of full term. (Their gestation period is 11 days, the shortest of any mammal, and marsupials are born premature relative to other mammals.) Selwoods interest in the technique was its potential use for conservation: breeding and preserving the species from frozen embryos, for example.

Only in the past few years have researchers, such as Magdalena Zernicka-Goetz at Cambridgeone of Prospects World Top 50 Thinkers last yearmanaged to grow human embryos in vitro right up to that 14-day limit. The difficulties, both practical and ethical, of investigating human embryos inside the womb mean that plenty remains unknown about their genetics, cell biology and tissue and organ formation. Ex utero studies beyond two weeks could potentially help us to understand and avoid, for example, miscarriages and growth defects that might cause disability or even death for babies carried to full term.

You neednt be a pro-lifer to accept there is still an urgent need to think all the consequences through

For all its humanitarian objectives, though, such research remains ethically fraught. A five-week-old human embryo, say, is very different from the shapeless mass of cells and folded tissues at 14 days: it has a shrimp-like form, with a rudimentary head, a neural tube that eventually becomes the central nervous system and brainas well as a beating heart. In other words, it is more recognisably human. (When the foetus can potentially feel pain is not clearthat has generally been deemed impossible before the brains cortex matures at around 24 weeks, but some argue that pain of a kind, if not an awareness of suffering, might be registered as early as 12 weeks.)

Of course, abortion of such embryos is permitted well into pregnancy in many countriesup to 24 weeks (and in exceptional cases later) in Great Britain. But technologies for gestation in artificial wombsboth for the early embryo as in the latest Israeli work, and life support for very premature babiescould seriously complicate the legal and ethical dilemmas. If these two methods, coming from opposite directions, meet in the middle so that the entire gestational period becomes technologically supportable, then genuine Huxlerian ectogenesis becomes an option. Women with potentially life-threatening pregnancies might then no longer be faced with termination as the only optionbut the law doesnt currently cover such a scenario. And how would abortion rights fare in the face of a putative technological solution that can preserve the life of the embryo or foetus? Its far from inconceivable that a state with strong anti-abortion leanings could mandate continued ex utero gestation rather than termination.

Such questions remain hypothetical: creating true artificial wombs is challenging, and the field has advanced at a snails pace for decades. But the latest work by Jacob Hanna and colleagues is a reminder of the direction of travel.

Sustaining human embryos beyond 14 days would not, however, currently be done with reproduction in mind. The aim is basic research for understanding developmental biology. An alternative approach for doing that, which would evade the 14-day rule, is to build synthetic embryo-like structures from stem cells. In the right conditions, you dont need to do much more than bring the right sorts of cells togetherthey will organise themselves spontaneously into a configuration more or less resembling an embryo. Two teams in the US and Australia have recently described the in vitro generation of human blastoidsstructures similar to early-stage embryosfrom stem cells either taken from actual embryos or reprogrammed from adult skin cells. These blastoids resemble the so-called blastocyst, the stage that a human embryo reaches around five to nine days after fertilisation, when it is ready to implant in the uterus wall. The blastoids contain not only the mass of stem cells that will become the foetus, but also the cell types that can develop into the tissues needed to sustain and contain it: the yolk sac and the placenta. The team in Texas showed that their blastoids could attach themselves to the culture dish to mimic uterine implantation, and then continue to develop.

Blastoids are just one example of what some have dubbed synthetic human entities with embryo-like features (SHEEFs); though simbryos is a catchier name. As they are not made by fertilisation of an egg by sperm, their legal and ethical status is unclear, and there is no consensus on regulation. UK and EU patent law rules that a synthetic cellular entity cant be considered a human embryo if in the light of current scientific knowledge, it does not, in itself, have the inherent capacity of developing into a human being. In the US an absence of federal laws might mean that the guidelines of the International Society for Stem Cell Research (ISSCR) are adopted. These were revised in May, and advise that such research be governed by case-by-case considerationbut that such entities should not be transferred to the uterus of either a human or another animal. Current simbryos almost certainly couldnt develop into a foetus in any casebut as they become ever better mimics of natural embryos, we cant be sure what potential they might have. Whether they could become babies is a crucial question, says bioethicist Hank Greely of Stanford University in California, but can we resolve that ethically? We wont know without trying it in humanswhich we cant do.

The edge of human

This science is in a Catch-22 situation, Greely says. We want to do research about humans that we cant ethically do on humans, so we go to non-human models. Existing non-human models [such as animals] arent that good, so we make new, better modelslike simbryos. But the dilemma is the better the models getthe more human they arethe more we get back into the same ethical issues. Biotechnologies like simbryos and chimeric embryos, suggest Greely and Bartha Maria Knoppers of McGill University in Montreal, are nibbling at the legal definition of what a human is.

The new ISSCR guidelines advise relaxation of the 14-day rule on human embryo research, to be replaced by a case-specific decision on what the limit should be. Changes to national legislation will be needed to enact this in many countries. But if that happens, some anticipate not only learning more about human embryo development but even harvesting nascent organs from such embryos, such as pancreases or kidneys, that might be grown further in vitro for transplantation. It might also be possible to use embryos grown for several weeks to test the safety of human gene editing, for example, to avoid some nasty genetic diseases.

History suggests that our response to disruptive technology will be highly dependent on contingent cultural preoccupations

Even with such potential medical benefits, you neednt be a pro-lifer to accept there is an urgent need to think all the consequences through. Our ability to transform, manipulate and culture cells takes us into uncharted territory where the boundaries of natural and artificial, and even of the human and non-human, are blurred. No off-the-shelf moral framework can be expected to guide the should and shouldnt. And history suggests that our response to disruptive technology will be highly dependent on contingent and perhaps ephemeral cultural preoccupations and prejudices. To track a responsible and humane path forward, we needsomehowto try and look beyond them.

Scientists lack the training and often the desire to take on that role. But the stifling of stem cell and embryo research in the US by George W Bushs 2001 Council on Bioethics shows what happens when religious conservatives are given the reins. As that panel showed, bioethics is a label that covers a multitude of sins and sometimes shows no inclination to examine its own assumptions. And heaven forbid that these issues be allowed to become fresh fuel for the culture wars. If we can reconstitute the collective and pragmatic wisdom of the Warnock Committee, it wont be a moment too soon.

The rest is here:
Replotting the human: the thorny ethics of growing babies outside the womb - Prospect

Crossroads of life: Jordan Reed’s journey through concussions, injuries and post-NFL healing – The Athletic

LEESBURG, Va. The 2020 season had just ended, and tight end Jordan Reed already was imagining an improved version of himself for 2021. Only 30 years old, the tight end dreamt of what could be his best year yet.

Then, while he was meditating one morning in his home in Palo Alto, Calif., it started.

Ringing in his ears.

He had heard it before, but it never lasted. This time, it wasnt going away.

Sometimes it was audible, sometimes just vibration. At times it was loud; other times soft. It could be a high-pitched squeal, almost like a dog whistle, or sound like a breeze through a tunnel. Sometimes it was a low-pitched buzz, as if it came from a speaker with a wiring problem.

The ringing was there when he was showering, pumping gas, throwing punches at his trainers mitts and watching his daughters soccer practice. It was worse when he tried to sleep.

Visit link:
Crossroads of life: Jordan Reed's journey through concussions, injuries and post-NFL healing - The Athletic

B-cell acute lymphoblastic leukemia: What to know – Medical News Today

B-cell acute lymphoblastic leukemia is a type of acute lymphoblastic leukemia (ALL). It is cancer that affects white blood cells known as B-cell lymphoblasts.

Lymphocytes form part of the immune system and protect the body against infections. People who have B-cell acute lymphoblastic leukemia have too many immature B-cell lymphoblasts in their bloodstream and bone marrow that do not work correctly.

As these leukemia cells increase, there are fewer healthy, mature white blood cells that fight infections and disease, red blood cells, and platelets. People with B-cell acute lymphoblastic leukemia may experience infections and anemia. They may also bleed easily.

B-cell lymphoblastic leukemia is the most common type of acute lymphoblastic leukemias or lymphomas, making up around 75% of adult leukemia cases. It can affect both adults and children.

This article looks at B cell acute lymphoblastic leukemia, as well as its causes, symptoms, and prognosis. It also explores how doctors diagnose and treat the condition.

ALL accounts for less than 0.5% of all cancers in the United States and 80% of these cases occur in children.

Doctors do not understand the exact cause of B-cell acute lymphoblastic leukemia. They do know that it involves the DNA in the bone marrow that controls how white blood cells divide, grow, and die.

In B-cell acute lymphoblastic leukemia, mutations or changes in the DNA mean that the cells do not follow the normal process of growth and maturation. Instead, the cells replicate and divide more rapidly and release immature white blood cells. These are called leukemia cells.

Mature B-cells mark infected cells with a protein, which other immune system cells then destroy. Leukemia cells are not capable of protecting the body from infection.

Scientists remain unsure why this happens but think it may be a combination of genetic and environmental factors.

Genetic changes can make someone more likely to develop leukemia by increasing the likelihood that mutations occur within their bone marrow.

For example, in adults, a change can happen if the DNA from a chromosome breaks off and attaches to a different chromosome. This is called translocation. In adults with ALL, the most common translocation is between chromosomes 9 and 22, and results in what is called the Philadelphia chromosome.

People with chromosomal conditions like Down syndrome also have an increased risk of developing B-cell acute lymphoblastic leukemia.

Usually, people develop the DNA mutations that can lead to ALL, rather than inheriting them. They may happen because the person had exposure to radiation or cancer-causing chemicals, but often the cause is unclear. Mutations can also occur because people have undergone radiotherapy and chemotherapy for other cancer.

Certain other factors can increase a persons risk of developing B-cell acute lymphoblastic leukemia, including high birth weight and smoking.

Many ALL symptoms are due to shortages of normal mature blood cells and can include:

People may also have a swollen abdomen due to a build-up of leukemia cells in the liver and spleen. If the leukemia cells build up near the surface of the bone or inside joints, this can cause pain.

Doctors diagnose ALL by using various tests to inspect the bone marrow or blood for signs of abnormal cells and to identify specific cells. Understanding someones diagnosis helps the doctor estimate how ALL may progress and determine the best treatment for them.

Tests may include:

Doctors confirm a diagnosis of ALL if 20% of the bone marrow cells are lymphoblasts.

There are no proven methods to prevent someone from developing leukemia. In general, people should avoid unnecessary exposure to cancer-causing chemicals like benzene, pesticides, and radiation as much as possible.

People should also avoid smoking and smoke inhalation, a risk factor for many cancers, including leukemias like ALL.

For adults with ALL, doctors usually use long-term chemotherapy. More intensive regimens may result in better responses but can cause more side effects, like low white blood cell counts.

Treatment usually has induction, consolidation, and maintenance phases that span around 2 years, although the ALL subtype and other factors can affect the length and intensity of the regime.

The first phase of treatment is induction therapy, which uses medication to help stabilize and reduce the number of lymphoblasts and regulate the individuals blood cell production. After this phase, for most people, the leukemia is in remission, meaning that there are no leukemia cells in bone marrow samples, and the person has normal blood counts.

The other stages of treatment aim to destroy any remaining leukemia cells in the body. The stages vary in length and intensity depending on how the leukemia responds.

Stem cell transplants are an option for some individuals to replace bone marrow affected by lymphoblasts with healthier, new bone marrow. Doctors need to match the donor bone marrow carefully to the individual.

Children with ALL receive a similar three-phase chemotherapy regime but may also need prolonged hospital stays for treatment, as infections and other complications can occur.

Children also receive chemotherapy in the cerebrospinal fluid (CSF) to kill any cancer cells in the brain and spinal cord.

The prognosis for individuals with B-cell acute lymphoblastic leukemia depends on various factors such as the persons age at diagnosis.

Children and young people are significantly more likely to undergo successful treatment and enter remission. For children with ALL, the 5-year survival rate is 85%. For adults with ALL, the 5-year survival rate is 69.9%.

A persons white blood cell count at the point of diagnosis also plays a role. People with a lower white blood cell count are more likely to make a full recovery. Additionally, how well a person responds to chemotherapy affects their recovery.

People who have concerns about ALL should contact their doctor or healthcare practitioner for advice. Cancer facilities often have support staff who can direct people to resources and support.

In the United States, the Leukemia and Lymphoma Society and American Cancer Society offer support and information for people living with ALL and other types of leukemia.

B-cell acute lymphoblastic leukemia is one of the most common types of leukemia in children but is rare in adults.

Various treatments aim to put the individual in remission and typically involve an extended chemotherapy regime.

The outlook for individuals with B-cell acute lymphoblastic leukemia is improving, especially among children, who often make a full recovery.

See the original post here:
B-cell acute lymphoblastic leukemia: What to know - Medical News Today

Chronic lymphocytic leukemia and stomach pain: What is the link? – Medical News Today

Chronic lymphocytic leukemia (CLL) is a type of blood cancer. It affects lymphocytes, a type of immature white blood cell that the body produces in the bone marrow.

People with CLL may experience discomfort, swelling, and pain in the abdomen if their spleen enlarges. In rare cases, CLL can also affect mucosal tissues, such as those lining the gastrointestinal (GI) tract.

This article discusses the link between CLL and stomach pain in more detail. It also looks at ways to prevent and treat CLL, the other possible symptoms, and the outlook for people with this condition.

People with CLL may experience various symptoms involving the abdomen or stomach, such as:

In most cases, people with CLL do not experience abdominal symptoms due to the disease until it progresses and becomes more severe.

Research suggests that CLL infiltrates and affects the GI tract in about 5.713% of cases. When CLL affects the GI tract, doctors may call it Richters syndrome.

People with CLL may experience abdominal swelling, discomfort, and tenderness as a result of their spleen becoming larger. Less commonly, they may also feel full after eating small amounts of food, as the spleen can press on the stomach, making it smaller and able to hold less.

In rare cases, CLL infiltrates the lining of the GI tract, causing inflammation and ulcers or open wounds. People may experience symptoms similar to those of inflammatory bowel disease (IBD) and malabsorption disorders. These symptoms may include diarrhea, nausea, vomiting, abdominal pain and cramping, and unintentional weight loss.

CLL is cancer that develops in lymphocytes, which are white blood cells that form in the bone marrow and help fight infection.

Lymphocytes make up most of the lymph tissues in the lymph nodes, thymus gland, adenoids, tonsils, and spleen. They are also present in the GI tract, bone marrow, and respiratory system.

CLL is a type of leukemia that develops gradually over time.

About 5075% of people with CLL do not experience noticeable symptoms. Due to this, doctors diagnose most people with CLL during routine blood work.

The symptoms of CLL often begin when the cancerous cells crowd out healthy cells in the bone marrow or migrate to other organs or tissues. When symptoms first appear, they are typically mild, but they then become increasingly severe. CLL can cause many nonspecific symptoms, so a person may feel as though they have a cold or the flu.

Possible symptoms of CLL that do not relate to the abdominal area include:

Doctors do not yet have a way to prevent leukemia. However, some types of leukemia, including CLL, may have links to toxins, such as herbicides, pesticides, radon, and tobacco exposure. People can help reduce the risk of CLL by avoiding or practicing extreme caution around these toxins.

Many people do not experience symptoms of CLL for years and do not require treatment. However, as the disease progresses, these individuals may need treatment to extend their lives.

When and how a doctor treats someones CLL depends on a few factors, including:

Chemotherapy is typically the first-line therapy for CLL.

Doctors may use chemotherapy in conjunction with other treatment options, such as monoclonal antibody therapy. This therapy binds antibodies to cancer cells and destroys them. Treatment can also include medications to treat or prevent infections or improve low blood cell levels.

For instance, some people may take a combination of the monoclonal antibody rituximab and the chemotherapy drugs fludarabine and cyclophosphamide. Alongside the oral chemotherapy medication chlorambucil, doctors use obinutuzumab or ofatumumab, which have the same drug target as rituximab.

Small molecule inhibitors, such as bendamustine hydrochloride, idelalisib, and ibrutinib, can also sometimes form part of a CLL treatment regimen.

In 2017, the Food and Drug Administration (FDA) approved the combination medication Rituxan Hyecela (rituximab and hyaluronidase human) for CLL treatment.

In recurring or aggressive cases of CLL, an individual may have a blood or bone marrow stem cell transplant. This procedure replaces diseased cells with healthy blood cells that are able to mature into bone marrow cells.

Doctors may treat CLL until the symptoms lessen and then stop treatment until the symptoms worsen again.

Many people with CLL live for many years with a high quality of life.

There is no cure for CLL, so treatment aims to extend and improve someones life by reducing their symptoms. Doctors treat many people intermittently as their symptoms reoccur.

A persons outlook depends on their age, overall health, underlying conditions, and stage of CLL. Typically, people who are over the age of 65 years or have a more advanced stage of CLL have a less positive outlook.

Genetic changes in CLL cells and increased beta-2 microglobulin protein levels in the blood can make CLL more challenging to treat, potentially affecting a persons outlook.

Doctors classify people with CLL into different risk groups depending on certain factors. Based on these risk groups, the estimated percentages of people surviving 5 years or more after their diagnosis is:

People with more advanced or severe CLL may experience abdominal swelling, discomfort, tenderness, and pain. They may also feel full after eating small amounts. More rarely, someone with CLL may develop GI tract inflammation or ulcers, which can cause symptoms such as diarrhea, nausea, vomiting, cramping, and unexplained weight loss.

Anyone who thinks that they may have CLL should speak with a doctor. People with a confirmed diagnosis who experience symptoms of more advanced or severe CLL, such as abdominal pain, should also seek medical care.

More:
Chronic lymphocytic leukemia and stomach pain: What is the link? - Medical News Today

Top 12 Disruptive Gene and Cell Therapy Technologies Announced – GlobeNewswire

Boston, MA, May 21, 2021 (GLOBE NEWSWIRE) -- Mass General Brigham today announced its selections for the sixth annual Disruptive Dozen, 12 emerging gene and cell therapy (GCT) technologies with the greatest potential to impact health care in the next few years. The technologies were featured as part of the World Medical Innovation Forum held virtually from Boston to examine GCTs potential to impact patient care including a range of diseases and health system opportunities.

The 2021 Mass General Brigham Disruptive Dozen are:

Researchers have pinpointed key genes involved in cholesterol and lipid metabolism that represent promising targets for new cholesterol-lowering treatments. Instead of disabling a disease-related protein, gene-silencing therapies prevent the protein from being made at all. That durability means patients could receive an injection of a gene-silencing drug every six months to control their blood cholesterol. Another transformative genetic medicine can alter the instructions written in a particular gene. Known as CRISPR base editing, this technology offers precision and potential permanence: patients may be able to undergo a one-time treatment and maintain healthy cholesterol levels for a lifetime.

Currently, devastating diseases such as sickle-cell disease and beta-thalessemia can only be cured by a bone marrow transplant, which can be risky and not feasible due to the lack of suitable donors. Now, new genome editors tools that make precise changes to a persons DNA are paving the way toward a different kind of cure. One approach uses a type of genome editing called CRISPR, and involves reactivating fetal hemoglobin, which can substitute for the missing or faulty adult version in these diseases. This CRISPR-based gene therapy is now being tested in clinical trials and early results are encouraging. Other gene therapies are also in the works, including those based on older technologies that augment rather than repair defective genes.

Genome editing technologies are having a significant impact across biomedicine, especially on the field of gene therapy. Despite their precision and ease of use, these tools cannot fix every genetic mutation, including those that change a single genetic base, similar to a one-letter misspelling on a page. More than 30,000 point mutations in the human genome are known to cause disease. Thanks to a new class of genome-editing tools, known as base editors, it is feasible to correct some of these so-called point mutations. The first base-editing therapies are now under development for a range of human diseases including sickle cell disease, inherited blindness, and genetic forms of high cholesterol. As base editing technologies continue to mature, researchers are also working to apply it to more common diseases, such as Alzheimers disease.

The first gene therapies to reach the clinic use viruses which have been molecularly honed and tailored to allow for the safe, effective delivery of human genes. While these viruses can transfer genes into cells a requirement for gene therapy they are not a perfect solution. Now, as scientists seek to build next-generation gene therapies, they are pursuing alternatives for gene delivery. These include highly sophisticated bubbles fashioned from nanoparticles, which help protect and direct gene therapies to their intended destination within the body. If gene therapies can be targeted more precisely to specific organs or tissues, they could be used to treat a broader range of disorders. These efforts are boosted by the recent development of a pair of highly effective coronavirus vaccines that use lipid-based nanoparticles to deliver their therapeutic cargo.

Some life-saving therapies, including certain forms of gene therapy, depend on bone marrow stem cells. But these cells are not easily accessible, and the protocol is long and can cause pain, nausea, and other complications. Scientists are developing a new approach that promises to streamline this process and help reduce the barriers that can hinder the delivery of some gene therapies. This new method holds promise not only for bone marrow transplantation, but also for gene therapies that depend on manipulating bone marrow stem cells. These treatments known broadly as ex vivo gene therapy require isolating bone marrow stem cells, treating the cells outside of the body with gene therapy, and then infusing the modified cells back into patients bloodstream.

One of the first gene therapies approved in the U.S. treats a rare genetic form of blindness with a one-time injection into the eye. Its success is paving the way for many other eye gene therapies that are now under development. Some 200 genes in humans are directly linked to vision problems, underscoring the incredible potential of the technology. Scientists are also pursuing novel gene therapies for another critical sensory organ, the ear. With more than 150 genes tied to hearing loss and deafness, there is a great need for treatments that can help protect and restore hearing. Millions of people in the U.S. suffer from hearing loss, yet there are currently no FDA-approved medicines to treat it. Unlike the eye, the inner ear is difficult to reach with therapeutics. To help overcome this hurdle, scientists have fine-tuned the molecular make-up of the viruses used in gene therapy to create versions that can penetrate the ears internal structures.

Approximately 10 million people worldwide suffer from Parkinsons disease, a chronic condition that stems from the progressive loss of dopamine-producing neurons in the brain, which help control movement. Unfortunately, there is no available drug that protects or stops the neurons from dying. But scientists and clinicians are developing a revolutionary approach to replace these lost neurons, harnessing stem cell-based methods to convert patients own blood cells into dopamine-producing neurons. Although this cell therapy does not fix the root causes of Parkinsons disease, it could provide a functional cure by replacing the dopamine-producing neurons in patients brains and restoring normal movement to their bodies.

Type 1 diabetes affects over a million people in the U.S. Patients must keep track of their blood sugar levels and inject themselves periodically with insulin, all because the cells in their own bodies that supply the hormone have been destroyed by the immune system. Scientists are working on a novel cell-based treatment for type 1 diabetes that involves replacing these lost insulin-producing cells with a special laboratory-grown variety. Over the last several years, scientists have developed several formulas for generating these cells using different stem cells as the key ingredient, along with cloaking strategies and efforts to enable replacement cells to release their own immune-blocking signals. As these technologies continue to advance toward the clinic, researchers hope to bring them to bear on another disease: type 2 diabetes. Worldwide there are over 400 million people with type 2 diabetes, many require insulin injections, underscoring the need for a more durable solution.

CAR-T therapy is a groundbreaking form of gene and cell therapy in which a patients own immune cells are isolated, genetically rewired in the laboratory with certain therapeutic properties, and then infused back into the bloodstream. For difficult to treat blood cancers, CAR-T therapies have proven remarkably effective, with some patients living for years cancer-free. Researchers are now working to expand the reach of this transformative technology by simplifying cell production and manufacturing and applying the approach to other disease areas. Scientists are also creating off-the-shelf versions of CAR-T therapies, selecting from an assortment of pre-made options for an immunological match for a patient. This could help expand the number of patients who could receive CAR-T therapies and minimize the time between doctors prescribing the treatment and patients receiving it. There are also efforts underway to broaden the diseases that CAR-T therapies can treat, including development of CAR-T therapies that can kill solid tumors or target entirely new areas, like autoimmune disease.

A virus found in nature has become a workhorse of gene therapy. Known asadeno-associated virus, or AAV, it is a popular choice among gene therapy developers because of its long track record and overall safety. But its not a perfect solution. Thats why scientists are working to create designer AAVs in the laboratory that address some of the virus shortcomings. The work promises to expand the clinical impact of gene therapy by broadening the number of patients and diseases that can benefit. Using data-driven methods, scientists are modifying the molecular make-up of the viruses to generate enhanced versions that home to specific organs, like the lung and kidney, which are not targeted by the current slate of therapeutic AAVs. Researchers are also fine-tuning AAVs to infect some cells in a tissue but not others for example, a specific subtype of neurons in the brain. Finally, efforts are underway to create AAVs that can evade detection by the immune system, which would help expand the clinical impact of gene therapy by making more patients eligible to receive it.

Some gene therapies seek to repair or replace whats been lost, like genes that are abnormally silent because of a genetic misspelling that terminates their usual function. But other genes can be broken in a different way that gives them new, often unexpected behaviors. To address these wayward genes, scientists have devised a class of innovative gene therapies called antisense oligonucleotides, or ASOs. They are designed with biochemical precision to shut down the activity of a target gene at its molecular roots and hold promise for neurodegenerative diseases. ASOs are relatively straightforward to engineer, so they can often be designed more quickly than other therapies. Over the last four years, six new ASO drugs were approved by the FDA, and many more are under development for a range of conditions, including neurodegenerative diseases such as ALS, Huntingtons disease, and Alzheimers disease.

Glioblastoma is the most common type of brain cancer in adults, and, tragically, most patients die within a year to 18 months of diagnosis. Now, using a variety of approaches from cancer-killing viruses to rewired immune cells to even cancer cells themselves researchers are working to develop a slate of innovative treatments with the power to eradicate glioblastoma tumors and give patients longer, cancer-free lives. One approach involves cancer-killing viruses, engineered in the laboratory to seek and destroy tumors. Researchers are also applying CAR-T cell technology, in which patients own immune cells are isolated, molecularly rewired with therapeutic powers, and then put back in the body. Another novel cell therapy builds on a remarkable, decade-old discovery: cancer cells that spread within the body can find their way back to their original tumor. This re-homing is spurring efforts to genetically engineer patients own tumor cells to endow them with cancer-killing properties. Once the cells are placed back into the body, they can return home and destroy their counterparts.

For detailed information on each of the Disruptive Dozen technologies, including video updates, please visit https://worldmedicalinnovation.org/2021-disruptive-dozen/

###

About Mass General Brigham Mass General Brigham is an integrated academic healthcare system, uniting great minds in medicine to make life-changing impact for patients in our communities and people around the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a non-profit organization that is committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nations leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. For more information, please visit massgeneralbrigham.org.

About Mass General Brigham Innovation Innovation is the 150-person business development unit of Mass General Brigham responsible for the worldwide commercial application of the unique capabilities and discoveries of Mass General Brigham's 74,000 employees. Innovation supports the research requirements of its 6,200 Harvard Medical School faculty and research hospitals. It has responsibility for industry collaborations, venture investing, international consulting, licensing, innovation management, company creation, technology marketing, open innovation alliances, and workforce development. Its annual World Medial Innovation Forum is underway virtually May 19-21.

Media Contact: Rich Copp Mass General Brigham: rcopp@partners.org

See the original post here:
Top 12 Disruptive Gene and Cell Therapy Technologies Announced - GlobeNewswire